Clinical trial · Observational
New Prospective Expanded German Registry of Incidental Gallbladder Carcinoma (PERSUASION)- a Permanent Platform Including All Kind of Biliary Tract Cancers (BTC)
NCT04896931CI-TRIAL-00100267completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Permanent, prospective, multicenter registry including all kind of oncological therapy lines and procedures, clinical outcome, translational research (biobanking) and QoL for all types of biliary tract cancers.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Biliary Tract Cancer | Malignant Biliary Tract Neoplasm | ALIAS | 0.90 |
| Neoadjuvant, Adjuvant and 1st Line | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Establishment of BTC population
- timeFrame
- Through study completion, an average of 2 years
- description
- To establish a representative BTC-patient population in German-speaking Europe in an agile platform study design for future research
Secondary outcomes (8)
- measure
- analyse potential risk factors associated with BTC-cancer
- timeFrame
- Through study completion, an average of 2 years
- description
- Correlate medical history with patient outcome, find prevalent medical history associated with BTC chancer
- measure
- The course of Quality of Life (QoL) throughout the entire course of therapy for patients with BTC
- timeFrame
- Through study completion, an average of 2 years
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Known biliary-tract cancer including intrahepatic-, extrahepatic- and gallbladder carcinomas * age ≥18 years * signed informed consent form * planned for (or recently started - i.e. within the last 21 days)) neoadjuvant, adjuvant or 1st line therapy Exclusion Criteria: * Patients who are unable to consent because they do not understand the nature, significance and implications of the registry and therefore cannot form a rational intention * Patient under 18 years of age * Patient's inability to complete QoL questionnaire or answer the questions. * Second-line or further palliative therapies if the patient's first-line therapy was not documented within the study.
References
Publications (0)
Data not yet available
No reference posted for this study.